Biomerica CEO buys 31,250 shares at $1.60 each

BIOMERICA INC (BMRA) reported an insider share purchase by Chief Executive Officer and director Zackary S. Irani.

Rhea-AI Filing Summary

BIOMERICA INC (BMRA) reported an insider share purchase by Chief Executive Officer and director Zackary S. Irani. On August 26, 2026, he purchased 31,250 shares of Biomerica common stock at $1.60 per share in a private placement conducted by Biomerica.

The transaction was made pursuant to a Securities Purchase Agreement dated August 20, 2026 involving certain institutional and individual investors, including B. Riley Principal Capital, LLC and certain members of Biomerica’s board and executive officers. Following this transaction, Irani directly holds 242,570 common shares.

Insider Trade Summary

Net Buyer: 31,250 shares

Net Buy 1 txn

Insider Irani Zackary S.

Role Chief Executive Officer

Bought 31,250 shs ($50K)

Type	Security	Shares	Price	Value
Purchase	Common stock F1	31,250	$1.60	$50K

Holdings After Transaction: Common stock — 242,570 shares (Direct)

Footnotes (1)

1. F1. On August 26, 2026, the reporting person acquired 31,250 shares of the Issuer's common stock at a purchase price of $1.60 per share in private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated August 20, 2026, by and among certain institutional and individual investors identified on the signature pages thereto, which included among others B. Riley Principal Capital, LLC and certain members of the Company's Board of Directors and executive officers.

Key Figures

Shares purchased: 31,250 shares of common stock Purchase price per share: $1.60 per share Shares owned after transaction: 242,570 shares of common stock +2 more

5 metrics

Shares purchased 31,250 shares of common stock Purchased on August 26, 2026 in a private placement

Purchase price per share $1.60 per share Price for the 31,250 shares acquired on August 26, 2026

Shares owned after transaction 242,570 shares of common stock Direct holdings of Zackary S. Irani following the purchase

Transaction date August 26, 2026 Date the private placement purchase was completed

Securities Purchase Agreement date August 20, 2026 Agreement governing the private placement

Key Terms

private placement, Securities Purchase Agreement, institutional investors, Beneficial ownership

4 terms

private placement financial

"acquired 31,250 shares ... at a purchase price of $1.60 per share in private placement by the Issuer"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

Securities Purchase Agreement financial

"pursuant to the terms of a Securities Purchase Agreement dated August 20, 2026"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

institutional investors financial

"by and among certain institutional and individual investors identified on the signature pages"

Institutional investors are large organizations, like pension funds, insurance companies, and mutual funds, that invest huge amounts of money on behalf of many people. Their decisions can influence the economy because they buy and sell big chunks of stocks, bonds, or other assets. They matter because their actions can affect market prices and trends.

Beneficial ownership financial

"the reporting person acquired 31,250 shares of the Issuer's common stock"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BMRA report for Zackary S. Irani?

Biomerica reported that CEO and director Zackary S. Irani purchased 31,250 shares of common stock on August 26, 2026 at $1.60 per share in a private placement by the company under a Securities Purchase Agreement dated August 20, 2026.

How many BMRA shares does Zackary S. Irani own after this transaction?

After the reported transaction, Zackary S. Irani directly holds 242,570 shares of Biomerica common stock. This figure reflects his position following the August 26, 2026 private placement purchase of 31,250 shares at $1.60 per share.

What was the price paid per share in the BMRA insider purchase?

The insider purchase by Biomerica CEO Zackary S. Irani was executed at a price of $1.60 per share for 31,250 shares of common stock in a private placement completed on August 26, 2026.

Was the BMRA insider transaction part of a private placement?

Yes. The filing states that on August 26, 2026, 31,250 shares of Biomerica common stock were acquired at $1.60 per share in a private placement by the issuer under a Securities Purchase Agreement dated August 20, 2026.

Who participated with the BMRA CEO in the August 2026 private placement?

The Securities Purchase Agreement dated August 20, 2026 covered certain institutional and individual investors, including B. Riley Principal Capital, LLC and certain members of Biomerica’s Board of Directors and executive officers, in addition to CEO Zackary S. Irani.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/27/2026 - 05:24 PM EDT Accepted by SEC EDGAR 08/27/2026 - 05:23 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Irani Zackary S.

(Last) (First) (Middle)

17571 VON KARMAN AVE

(Street)

IRVINE CALIFORNIA 92614

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOMERICA INC [ BMRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	08/26/2026		P		31,250(1)	A	$1.6	242,570	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On August 26, 2026, the reporting person acquired 31,250 shares of the Issuer's common stock at a purchase price of $1.60 per share in private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated August 20, 2026, by and among certain institutional and individual investors identified on the signature pages thereto, which included among others B. Riley Principal Capital, LLC and certain members of the Company's Board of Directors and executive officers.

	/s/ Zackary S. Irani	08/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)